Fagervall I, Ross S B
Department of Neuropharmacology, Astra Alab AB, Södertälje, Sweden.
J Neurochem. 1989 Feb;52(2):467-71. doi: 10.1111/j.1471-4159.1989.tb09144.x.
The irreversible inhibition of the monoamine oxidase (MAO) activity within monoaminergic neurons in the rat brain 24 h after single or repeated administration of (E)-beta-fluoromethylene-m-tyrosine (FMMT, MDL 72394) was examined. The enzyme activity was determined by incubating synaptosome-rich homogenates of hypothalamus or striatum with low concentrations of 5-[14C]hydroxytryptamine (5-HT), [14C]noradrenaline (NA), or [14C]dopamine (DA) in the absence and presence of the selective amine uptake inhibitors citalopram (5-HT), maprotiline (NA), and GBR 12909 (DA). After a single subcutaneous injection of FMMT, the inhibition of MAO within the noradrenergic and dopaminergic neurons was significant but only slightly greater than that outside these neurons. The opposite relationship was observed for the serotonergic neurons. After 7 days' treatment of rats with carbidopa, 20 mg/kg p.o., + FMMT once daily, the preference for the inhibition of MAO within the noradrenergic and dopaminergic neurons was accentuated further. The inhibition outside the serotonergic neurons was still greater than within these neurons. The NA uptake inhibitor CPP 199 antagonized the selective inhibition of MAO within the noradrenergic neurons, which indicates that this preference is due to the accumulation of the active metabolite (E)-beta-fluoromethylene-m-tyramine by the NA transporter.
研究了单次或重复给予(E)-β-氟亚甲基间酪氨酸(FMMT,MDL 72394)24小时后大鼠脑中单胺能神经元内单胺氧化酶(MAO)活性的不可逆抑制情况。通过在有无选择性胺摄取抑制剂西酞普兰(5-羟色胺)、马普替林(去甲肾上腺素)和GBR 12909(多巴胺)存在的情况下,将富含突触体的下丘脑或纹状体匀浆与低浓度的5-[14C]羟色胺(5-HT)、[14C]去甲肾上腺素(NA)或[14C]多巴胺(DA)一起孵育来测定酶活性。单次皮下注射FMMT后,去甲肾上腺素能和多巴胺能神经元内MAO的抑制作用显著,但仅略大于这些神经元外的抑制作用。对于5-羟色胺能神经元则观察到相反的关系。在用卡比多巴(20mg/kg口服)+ FMMT每日一次对大鼠进行7天治疗后,对去甲肾上腺素能和多巴胺能神经元内MAO抑制的偏好进一步加剧。5-羟色胺能神经元外的抑制作用仍大于这些神经元内的抑制作用。去甲肾上腺素摄取抑制剂CPP 199拮抗去甲肾上腺素能神经元内MAO的选择性抑制,这表明这种偏好是由于去甲肾上腺素转运体对活性代谢物(E)-β-氟亚甲基间酪胺的积累所致。